PHIO PHARMACEUTICALS CORP

PHIO insiders, led by Ronald Todd Plott, boost confidence with a 42k‑share buying spree—potential catalyst for a rebound amid volatile biotech market.

Phio insider buy: Ronald Todd’s 17,000‑share purchase signals confidence in Phio Pharma’s cancer immunotherapy prospects and potential upside despite volatility.

Patricia A. Bradford’s steady insider buying shows confidence in Phio Pharmaceuticals’ cancer‑immunotherapy pipeline, hinting at a future rebound.

Robert Bitterman’s latest 2,000‑share buy at Phio Pharmaceuticals signals confidence amid a volatile stock, but mixed insider activity and weak fundamentals urge cautious watch.

Patricia A. Bradford’s recent insider buy at Phio Pharmaceuticals signals confidence in the company’s oncology pipeline, hinting at future upside amid a quiet market.

PHIO Pharma insider sale: CEO’s tax‑related sell keeps control steady, while PH‑762 Phase 2b milestone signals potential upside for long‑term investors.